Ex Vivo Stem Cell Editing vs In Vivo Gene Therapy
The two dominant paradigms in gene therapy differ fundamentally in where editing happens. Ex vivo approaches remove a patient's cells (usually hematopoietic stem cells), edit them in the lab with CRISPR or lentiviral vectors, verify the edits, and infuse them back. In vivo approaches deliver the editing machinery directly into the patient's body, targeting organs like the liver, eye, or muscle. Both have FDA-approved products, but each carries distinct trade-offs in safety, scalability, cost, and the range of diseases they can treat.
Last updated: March 30, 2026
Ex Vivo Stem Cell Editing
Cells are extracted from the patient, gene-edited or gene-modified in a GMP lab, quality-checked, expanded, and reinfused. The standard approach for blood disorders and many cancers. Requires myeloablative conditioning (busulfan chemotherapy) to make room for edited cells.
In Vivo Gene Therapy
Editing machinery (AAV vectors, lipid nanoparticles carrying CRISPR components, or direct injection) is delivered into the patient's body to edit cells in their natural location. Targets organs that are difficult to access ex vivo — liver, eye, brain, muscle.
Key Specifications
| Feature | Ex Vivo Stem Cell Editing | In Vivo Gene Therapy |
|---|---|---|
| Where editing happens | Lab (outside body) | Inside patient's body |
| Key delivery method | Electroporation / lentiviral transduction | AAV vectors / lipid nanoparticles |
| FDA-approved examples | Casgevy, Lyfgenia, Kymriah, Yescarta | Luxturna, Zolgensma, Hemgenix, Elevidys |
| Diseases treated | Blood disorders, cancers, immunodeficiencies | Eye disease, SMA, hemophilia, liver disease |
| Typical cost | $475K–$3.1M per patient | $850K–$3.5M per patient |
| Manufacturing time | 4-8 weeks (autologous) / off-the-shelf (allogeneic) | Batch production (scalable) |
| Safety verification | Pre-infusion QC, sequencing, off-target analysis | Post-administration monitoring only |
| Re-dosing possible | Yes (new cell harvest) | Difficult (anti-AAV immunity); LNPs may allow re-dosing |
| Conditioning required | Yes — myeloablative busulfan for HSPC therapies | No conditioning needed |
| Organs accessible | Blood cells, immune cells | Liver, eye, muscle, CNS, heart |
Ex Vivo Stem Cell Editing
Advantages
- Edits can be verified and quality-controlled before infusion — highest safety for off-target checking
- FDA-approved products: Casgevy (CRISPR, SCD/thalassemia), Lyfgenia (lentiviral, SCD), Kymriah/Yescarta (CAR-T, cancer)
- Proven durability — Casgevy patients show 97% freedom from crises at 12+ months
- Can perform complex multi-gene edits (allogeneic CAR-T: knockout TCR + HLA + add CAR)
- Patient's own cells reduce immune rejection risk (autologous approaches)
Limitations
- Requires harsh myeloablative conditioning (busulfan) — significant side effects including infertility risk
- Manufacturing takes 4-8 weeks per patient (except FasTCAR: 22-36 hours)
- Extremely expensive: $2.2M (Casgevy), $3.1M (Lyfgenia), $475K (CAR-T)
- Limited to accessible cell types — cannot edit neurons, cardiomyocytes, hepatocytes in situ
- Requires specialized GMP manufacturing facilities at each treatment center
In Vivo Gene Therapy
Advantages
- Single infusion/injection — no cell extraction, no conditioning chemotherapy required
- Can reach organs impossible to edit ex vivo: liver (NTLA-2001), eye (Luxturna), muscle (Zolgensma/Elevidys)
- FDA-approved products: Luxturna (eye, $850K), Zolgensma (SMA, $2.1M), Hemgenix ($3.5M)
- Scalable manufacturing — one batch of AAV or LNP can treat many patients
- Intellia NTLA-2001 showed 93% TTR knockdown sustained for 3+ years with single dose
Limitations
- Cannot verify edits before they happen — off-target effects are irreversible
- Immune response to viral vectors (AAV) can limit re-dosing and cause inflammation
- Pre-existing AAV antibodies disqualify 30-50% of patients from AAV-based therapies
- Biodistribution control is imperfect — LNPs mainly target liver; reaching other organs is harder
- Verve VERVE-101 safety signal (patient death) highlighted risks of permanent cardiovascular edits
The Verdict
Both approaches are clinically validated and FDA-approved, but they serve complementary rather than competing roles. Ex vivo stem cell editing dominates blood disorders and cancers because HSPCs are easily accessible and edits can be verified — Casgevy and CAR-T therapies have transformed these fields. In vivo gene therapy is essential for diseases affecting organs that cannot be removed and edited — Luxturna restored vision, Zolgensma saves infants from SMA, and Intellia's NTLA-2001 proved that one-time liver gene editing is durable. The future likely combines both: CRISPR-edited iPSC-derived cells (ex vivo) for universal off-the-shelf therapies, and improved LNP delivery (in vivo) to reach beyond the liver. For investors, the split is clear: ex vivo for near-term blood/cancer returns, in vivo for the larger long-term addressable market of organ-specific diseases.